Bing Center for Waldenstrom's Macroglobulinemia

ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online. As in the past, they provide abstracts online via the conference website. The scientific program will take place May 29 through May 31.

ASCO20 Website: https://meetings.asco.org/am/virtual-welcome

There are 8 abstracts specific to Waldenstrom's Macroglobulinemia:

Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)

Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM)

Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials

Bendamustine (B) + methylprednisolone (MP) and peg-filgastrim in indolent lymphoma

Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study

Survival from time of transformation in patients with transformed lymphoma at time of diagnosis